Drugs / 18F-PM-PBB3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04242056 | Feb → Sep 2020 | multiple sclerosis | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04248270 | Feb 2020 → Aug 2023 | Alzheimer disease, vascular dementia | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]PM-PBB3 | “A noval tau tracer [18F]PM-PBB3, which had substantially improved the off-target binding and more clear background in human brain than previous tau tracer.” NCT04248270 ↗ |